Want to see CH:ROP full AI Analyst Report?
ROP Stock Chart & Stats
CHF355.10
CHF5.00(1.41%)
At close: 4:00 PM EDT
CHF355.10
CHF5.00(1.41%)
Day’s Range― - ―
52-Week RangeCHF243.90 - CHF374.90
Previous CloseN/A
Volume847.17K
Average Volume (3M)1.25M
Market Cap
CHF287.02B
Enterprise ValueCHF294.66K
Total Cash (Recent Filing)CHF9.73B
Total Debt (Recent Filing)CHF31.80B
Price to Earnings (P/E)24.0
Beta1.28
Next Earnings
Feb 04, 2027EPS Estimate
9.97Next Dividend Ex-DateN/A
Dividend Yield2.66%
Share Statistics
EPS (TTM)15.36
Shares Outstanding702,562,700
10 Day Avg. Volume1,308,571
30 Day Avg. Volume1,251,256
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF352.06Price Target Upside-0.86% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)20.21
Revenue Forecast (FY)CHF63.19B
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyFenebrutinib demonstrated roughly half the relapse rate versus the comparator and showed consistent reductions in brain lesions and progression measures, indicating meaningful clinical benefit.
Label Expansion PotentialA label that permits switching from aromatase inhibitor monotherapy could substantially expand the giredestrant-eligible population, and additional switch data could support such an indication.
Market Opportunity In Breast CancerGiredestrant targets the majority of hormone receptor–positive, HER2‑negative breast cancer patients and appears better tolerated than standard therapy, creating potential for broad adjuvant uptake.
Bears Say
Hepatic Safety RiskElevated liver enzymes and cases meeting biochemical Hy's law in another trial point to potential hepatotoxicity that may require additional monitoring or restrictive labeling.
Mortality Safety SignalA higher count of fatal cases in the fenebrutinib arm compared with the comparator represents a serious safety signal that could limit regulatory approval and clinician adoption.
Regulatory And Evidence HurdlesSafety concerns combined with the need for definitive randomized studies for combination regimens create regulatory and reimbursement risks that could delay broader use.
ROP FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was CHF243.90 and its highest was CHF374.90 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is CHF287.02B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Feb 04, 2027 which is in 190 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 23, 2026. The company reported CHF10.85 earnings per share for the quarter, beating the consensus estimate of CHF10.33 by CHF0.52.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Overvalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of CHF9.8 which represents an annual dividend yield of 2.66%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 9.97.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of CHF10.85 in its last earnings report, beating expectations of CHF10.33. Following the earnings report the stock price went up 5.144%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in CH:ROP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding AG
Roche Holding AG is a prominent global entity primarily active in the pharmaceutical and diagnostics industries. Its extensive operations encompass numerous countries, including key markets such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside a broader international presence. The company's pharmaceutical division is dedicated to developing and marketing a diverse range of medicinal products. These treatments target various therapeutic areas like oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory conditions. Additionally, their portfolio addresses specific ailments such as anemia, cancer, dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation. In the diagnostics sector, Roche supplies advanced in-vitro tests utilized for detecting and monitoring a wide array of diseases, including cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. They also provide crucial diagnostic instruments and reagents to healthcare facilities. Furthermore, Roche is engaged in a research partnership with Synlogic, Inc., focused on identifying a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). This well-established organization, founded in 1896, maintains its corporate headquarters in Basel, Switzerland.
ROP Company Deck
ROP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum (core operating profit +10%, margin expansion, robust cash flow) combined with substantial pipeline and regulatory momentum (5 FDA priority reviews, 80% Phase III success YTD, multiple product launches/CE marks, and strategic diagnostics M&A). Headwinds were acknowledged and specific: China diagnostics pricing reform, weaker respiratory season, currency translation effects, net debt increase from dividends/timing, competitive pressures (biosimilars) and some impairments. Overall, the positive operational and pipeline developments materially outweigh the challenges, and management maintained confident guidance (mid-single-digit sales growth, high-single-digit core EPS growth) while flagging manageable near-term risks.View all CH:ROP earnings summariesROP Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
CHF352.06
▼(-0.86% Downside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month











